| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 04/28/2011 | CA2778497A1 Cell free cd4 quantitation and methods of use |
| 04/28/2011 | CA2778391A1 A means for inducing apomixis in cultivated plants having sexual reproduction and use thereof for the production of completely or partially apomictic plants |
| 04/28/2011 | CA2778390A1 Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions |
| 04/28/2011 | CA2778359A1 Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof |
| 04/28/2011 | CA2777758A1 Peptidic glp-2 agonists |
| 04/28/2011 | CA2777753A1 Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
| 04/28/2011 | CA2777159A1 Detection of a circovirus in calves suffering from bovine neonatal pancytopenia |
| 04/28/2011 | CA2774871A1 Screening method utilizing thalidomide-targeting factor |
| 04/28/2011 | CA2773396A1 Methods and systems for purifying non-complexed botulinum neurotoxin |
| 04/27/2011 | EP2315017A1 Method for detection of fibromyalgia |
| 04/27/2011 | EP2314719A1 S. pneumoniae antigens |
| 04/27/2011 | EP2314718A1 S. pneumoniae antigens |
| 04/27/2011 | EP2314716A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/27/2011 | EP2314712A1 Expression vectors encoding epitopes of antigens and methods for their design |
| 04/27/2011 | EP2314699A1 Medical preparations for the treatment of alpha-galactosidase A deficiency |
| 04/27/2011 | EP2314697A1 Streptococcus pneumoniae proteins and nucleic acids |
| 04/27/2011 | EP2314696A1 Therapeutic uses of human Interleukin-B50 antagonist. |
| 04/27/2011 | EP2314695A2 Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| 04/27/2011 | EP2314694A2 BAFF receptor (BCMA), an immunoregulatory agent |
| 04/27/2011 | EP2314690A1 RNA-interference by single-stranded RNA molecules |
| 04/27/2011 | EP2314684A1 Fluorescent protein and chromoprotein |
| 04/27/2011 | EP2314683A1 Fluorescent protein and chromoprotein |
| 04/27/2011 | EP2314682A2 Fluorescent protein |
| 04/27/2011 | EP2314681A1 Modified biotin-binding protein |
| 04/27/2011 | EP2314676A1 Compositions and methods for the treatment of immune related diseases |
| 04/27/2011 | EP2314668A2 Gene inactivated mutants with altered protein production |
| 04/27/2011 | EP2314667A2 Gene inactivated mutants with altered protein production |
| 04/27/2011 | EP2314630A1 Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes |
| 04/27/2011 | EP2314629A1 Recombinant production of mixtures of antibodies |
| 04/27/2011 | EP2314625A1 Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| 04/27/2011 | EP2314616A1 Peptidic GLP-2 agonists |
| 04/27/2011 | EP2314615A2 Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them |
| 04/27/2011 | EP2314614A1 Anti-angiogenic methods and compositions |
| 04/27/2011 | EP2314613A2 Genetic products which are differentially expressed in tumours and use thereof |
| 04/27/2011 | EP2314612A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314611A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314610A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314609A1 Metastin derivative and use thereof |
| 04/27/2011 | EP2314608A1 Stabilisation of biosensors for in vivo applications |
| 04/27/2011 | EP2314607A1 Polypeptides involved in regulation of sugar and lipid metabolism and methods of use VIII |
| 04/27/2011 | EP2314606A1 Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use VIII |
| 04/27/2011 | EP2314605A1 Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| 04/27/2011 | EP2314604A2 Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof |
| 04/27/2011 | EP2314603A2 Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof |
| 04/27/2011 | EP2314602A1 Improved expression systems with SEC-system secretion |
| 04/27/2011 | EP2314601A1 Anti-inflammatory compounds and uses thereof |
| 04/27/2011 | EP2314596A2 DNA-Polymerase blends and mutant DNA polymerases |
| 04/27/2011 | EP2314320A2 Method for shielding functional sites or epitopes on proteins |
| 04/27/2011 | EP2314317A2 Anti-glypican 3 antibody |
| 04/27/2011 | EP2314314A2 Chlamydia trachomatis antigens for vaccine and diagnostic use |
| 04/27/2011 | EP2314312A2 Peptides and therapeutic application therefof |
| 04/27/2011 | EP2314311A2 Peptides and therapeutic application thereof |
| 04/27/2011 | EP2314310A2 Identification of surface-associated antigens for tumour diagnosis and therapy |
| 04/27/2011 | EP2314309A2 Identification of surface-associated antigens for tumour diagnosis and therapy |
| 04/27/2011 | EP2314308A1 Use of microproteins as tryptase inhibitors |
| 04/27/2011 | EP2314306A1 Biological pacemaker |
| 04/27/2011 | EP2314305A2 Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| 04/27/2011 | EP2313510A2 Glutamate decarboxylase (gad) transgenic plants with enhanced nitrogen uptake and utilisation |
| 04/27/2011 | EP2313508A1 Plants having enhanced yield-related traits and a method for making the same |
| 04/27/2011 | EP2313503A2 Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof |
| 04/27/2011 | EP2313432A1 Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders |
| 04/27/2011 | EP2313431A2 Long-acting interferons and derivatives thereof and methods thereof |
| 04/27/2011 | EP2313430A1 Muteins of hngal and related proteins with affinity for a given target |
| 04/27/2011 | EP2313429A1 Msp-1 protein preparations from plasmodium |
| 04/27/2011 | EP2313428A2 Recombinant human parainfluenza type 1 viruses (hpiv1s) containing mutations in or deletion of the c protein are attenuated in african green monkeys and in ciliated human airway epithelial cells and are potential vaccine candidates for hpiv1 |
| 04/27/2011 | EP2313427A2 Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides |
| 04/27/2011 | EP2313105A1 SOLUBLE HYBRID Fc RECEPTORS AND RELATED METHODS |
| 04/27/2011 | EP1987052B1 Synthesis of glucagon-like peptides |
| 04/27/2011 | EP1732947B1 Growth factor binding constructs materials and methods |
| 04/27/2011 | EP1713828B1 Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide |
| 04/27/2011 | EP1682665B1 Use of fibroblast growth factor fragments |
| 04/27/2011 | EP1551977B1 Selective, local activation of members of the tnf ligand family of systemically inactive non-antibody tnf ligand fusion proteins |
| 04/27/2011 | EP1524994B1 Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 04/27/2011 | EP1456394B2 Methods of using improved polymerases |
| 04/27/2011 | EP1419175B1 Replikin peptides and uses thereof |
| 04/27/2011 | EP1368373B1 Environmentally regulated genes, involved in the virulence of streptococcus suis |
| 04/27/2011 | EP1317470B1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate tumor therapy |
| 04/27/2011 | EP1272633B1 Compositions and methods for dendritic cell-based immunotherapy |
| 04/27/2011 | EP1118660B1 Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme |
| 04/27/2011 | EP0972031B1 Procollagen assembly |
| 04/27/2011 | CN1845995B Chimeric antigens for breaking host tolerance to foreign antigens |
| 04/27/2011 | CN1798836B Methods for preventing gluconoylation of proteins |
| 04/27/2011 | CN102037362A Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| 04/27/2011 | CN102037359A Method for evaluation of function of phagocyte |
| 04/27/2011 | CN102037136A Products and their use for the diagnosis, prevention, and/or care of human and/or animal pathologies characterised by the anomalous deposition of beta-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, and screening method for determining the risk of such pathologies |
| 04/27/2011 | CN102037132A Methods for enhanced production of bone morphogenetic proteins |
| 04/27/2011 | CN102037126A Method and gene for imparting or enhancing nonspecific adherence and/or aggregability to microorganism |
| 04/27/2011 | CN102037125A Use of rice polypeptides/nucleic acids for plant improvement |
| 04/27/2011 | CN102037124A hERG mutants and uses thereof |
| 04/27/2011 | CN102037009A Process |
| 04/27/2011 | CN102037008A Protease stabilized, acylated insulin analogues |
| 04/27/2011 | CN102037007A Selective exosite inhibition of PAPP-A activity against IGFBP-4 |
| 04/27/2011 | CN102037006A Anti-bacterial compositions |
| 04/27/2011 | CN102036682A Set of antiangiogenic molecules and use thereof |
| 04/27/2011 | CN102036679A Treating dyspnea associated with acute heart failure with relaxin |
| 04/27/2011 | CN102036678A Use of defensins against meningitis |
| 04/27/2011 | CN102031244A Recombinant mesenchymal stem cell and preparation method and application thereof |
| 04/27/2011 | CN102031236A Heat resistant N-acyl-homoserine lactonase AiiA-AI96 as well as coding gene and application thereof |
| 04/27/2011 | CN102030823A Liver-targeted genetically engineered interferon and preparation method thereof |
| 04/27/2011 | CN102030822A New human cell factor VSTM1-v2 and application thereof |